Search

Your search keyword '"Veronese, Silvio Marco"' showing total 9 results
Start Over Author "Veronese, Silvio Marco" Database Supplemental Index
9 results on '"Veronese, Silvio Marco"'

1. Evolutionary Portrait of Adult Core-Binding Factor Leukemia Patients Treated with a Continuation Therapy with Midostaurin: Preliminary Results

Author

Cairoli, Roberto, Gatti, Arianna, Grillo, Giovanni, Fumagalli, Monica, Krampera, Mauro, Zappasodi, Patrizia, Borlenghi, Erika, Todisco, Elisabetta, Ubezio, Marta, Bernardi, Massimo, Molteni, Alfredo, Basilico, Claudia, Turrini, Mauro, Greco, Rosa, Mancini, Valentina, Riva, Marta, De Marco, Beatrice, Stefanucci, Marta Rachele, Brando, Bruno, Veronese, Silvio Marco, and Beghini, Alessandro

Published
2022
Full Text
View/download PDF

2. Evolutionary Portrait of Adult Core-Binding Factor Leukemia Patients Treated with a Continuation Therapy with Midostaurin: Preliminary Results

Author

Cairoli, Roberto, Gatti, Arianna, Grillo, Giovanni, Fumagalli, Monica, Krampera, Mauro, Zappasodi, Patrizia, Borlenghi, Erika, Todisco, Elisabetta, Ubezio, Marta, Bernardi, Massimo, Molteni, Alfredo, Basilico, Claudia, Turrini, Mauro, Greco, Rosa, Mancini, Valentina, Riva, Marta, De Marco, Beatrice, Stefanucci, Marta Rachele, Brando, Bruno, Veronese, Silvio Marco, and Beghini, Alessandro

Published
2022
Full Text
View/download PDF

3. Repotrectinib Overcomes F2004V Resistance Mutation in ROS1-Rearranged NSCLC: A Case Report

Author

Pizzutilo, Elio Gregory, Agostara, Alberto Giuseppe, Roazzi, Laura, Romanò, Rebecca, Motta, Valentina, Lauricella, Calogero, Marrapese, Giovanna, Cerea, Giulio, Signorelli, Diego, Veronese, Silvio Marco, Giannetta, Laura Giuseppina, Sartore-Bianchi, Andrea, and Siena, Salvatore

Abstract

ROS1 tyrosine kinase inhibitors (TKIs) were found to provide a substantial clinical benefit for patients with advanced ROS1-positive (ROS1+) NSCLC. Nevertheless, TKI resistance inevitably develops with different mechanisms, preventing prolonged responses. For this reason, next-generation compounds are under clinical development. ROS1 F2004 substitutions have been previously detected on circulating tumor DNA of patients progressing to entrectinib. Hereby, we report the case of a patient with ROS1+ NSCLC in which F2004V-acquired mutation was detected on a site of disease progression, after entrectinib and crizotinib failure. A subsequent treatment with next-generation TKI repotrectinib led to disease response, providing the first clinical evidence of activity of repotrectinib against F2004V resistance mutation.

Published
2023
Full Text
View/download PDF

4. Enasidenib, an Oral Therapy in Mutant IDH2 Relapsed/Refractory Acute Myeloid Leukemia: A Real-Life Single Center Experience

Author

Riva, Marta, Rizzo, Lorenzo, Mancini, Valentina, Greco, Rosa, Bertani, Giambattista, Zucchetti, Elisa, Diral, Elisa, Nichelatti, Michele, Veronese, Silvio Marco, Grillo, Giovanni, and Cairoli, Roberto

Abstract

Veronese: Janssen Cilag:Honoraria;Bayer:Honoraria;Novartis:Other: Travel Expenses;AstraZeneca:Other: Travel Expenses.

Published
2020
Full Text
View/download PDF

5. Prospective Evaluation of a Continuation Therapy with Midostaurin in Adult Patients with Core-Binding Factor Leukemia and Integrated Genetic Analysis: A Multi Center Phase II Study. Preliminary Results

Author

Cairoli, Roberto, Krampera, Mauro, Zappasodi, Patrizia, Todisco, Elisabetta, Borlenghi, Erika, Molteni, Alfredo, Fumagalli, Monica, Ubezio, Marta, Bernardi, Massimo, Greco, Rosa, Ravelli, Erika, Mancini, Valentina, Grillo, Giovanni, Riva, Marta, De Marco, Beatrice, Cassaro, Adriana, Brando, Bruno, Gatti, Arianna, Veronese, Silvio Marco, and Beghini, Alessandro

Abstract

Krampera: Janssen: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees. Todisco:Jannsen, Abbvie, Jazz: Membership on an entity's Board of Directors or advisory committees. Veronese:Novartis: Other: Travel Expenses; Bayer: Honoraria; AstraZeneca: Other: Travel Expenses; Janssen Cilag: Honoraria.Midostaurin for treatment of Core Binding Factor Leukemia. The drug has been used as KIT inhibitor.

Published
2020
Full Text
View/download PDF

6. Prospective Evaluation of a Continuation Therapy with Midostaurin in Adult Patients with Core-Binding Factor Leukemia and Integrated Genetic Analysis: A Multi Center Phase II Study. Preliminary Results

Author

Cairoli, Roberto, Krampera, Mauro, Zappasodi, Patrizia, Todisco, Elisabetta, Borlenghi, Erika, Molteni, Alfredo, Fumagalli, Monica, Ubezio, Marta, Bernardi, Massimo, Greco, Rosa, Ravelli, Erika, Mancini, Valentina, Grillo, Giovanni, Riva, Marta, De Marco, Beatrice, Cassaro, Adriana, Brando, Bruno, Gatti, Arianna, Veronese, Silvio Marco, and Beghini, Alessandro

Abstract

Genetic and Clinical Background:

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results